From the Departments of *Otolaryngology, and †Radiology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Clin Nucl Med. 2015 Jun;40(6):464-8. doi: 10.1097/RLU.0000000000000652.
The present study compared the potential of pretreatment 3'-deoxy-3'-[F]-fluorothymidine (F-FLT) uptake parameters and those of F-FDG to predict the clinical outcome of head and neck squamous cell carcinoma treated with chemoradiotherapy.
A total 53 patients undergoing pretreatment F-FLT PET/CT and F-FDG PET/CT from May 2006 to April 2013 were evaluated. The SUVmax, metabolic tumor volume (MTV), total lesion glycolysis, and total lesion proliferation (TLP) were determined semiquantitatively. Associations between clinical factors and PET/CT parameters and prognostic value were analyzed.
In univariate analyses, F-FLT SUVmax, MTV, TLP, F-FDG MTV, and total lesion glycolysis correlated with locoregional control (P = 0.02, P = 0.0007, P = 0.0001, P = 0.007, and P = 0.013, respectively). Clinical T stage, F-FLT SUVmax, MTV, TLP, and F-FDG SUVmax correlated with overall survival (P = 0.012, P = 0.0057, P = 0.0018, P = 0.0012, and P = 0.047, respectively). On multivariate analyses, F-FLT TLP was an independent factor for locoregional control (P = 0.002; hazards ratio [HR], 5.13; 95% confidence interval [CI], 1.81-14.54), as were F-FLT SUVmax and MTV for overall survival (P = 0.021; HR, 3.47; 95% CI, 1.2-10.01 and P = 0.029; HR, 3.17; 95% CI, 1.12-8.95).
Pretreatment F-FLT PET/CT volume-based metabolic parameters are superior prognostic predictors to those of F-FDG PET/CT. F-FLT SUVmax and MTV can provide important prognostic information for patients with head and neck squamous cell carcinomas administered with chemoradiotherapy.
本研究比较了预处理 3'-脱氧-3'-[F]-氟胸苷(F-FLT)摄取参数和 F-FDG 的潜力,以预测接受放化疗的头颈部鳞状细胞癌的临床结果。
本研究共纳入了 2006 年 5 月至 2013 年 4 月期间进行预处理 F-FLT PET/CT 和 F-FDG PET/CT 的 53 例患者。采用半定量方法测定 SUVmax、代谢肿瘤体积(MTV)、总病变糖酵解和总病变增殖(TLP)。分析了临床因素与 PET/CT 参数之间的相关性及其预后价值。
在单因素分析中,F-FLT SUVmax、MTV、TLP、F-FDG MTV 和总病变糖酵解与局部区域控制相关(P=0.02、P=0.0007、P=0.0001、P=0.007 和 P=0.013)。临床 T 分期、F-FLT SUVmax、MTV、TLP 和 F-FDG SUVmax 与总生存相关(P=0.012、P=0.0057、P=0.0018、P=0.0012 和 P=0.047)。在多因素分析中,F-FLT TLP 是局部区域控制的独立因素(P=0.002;风险比[HR],5.13;95%置信区间[CI],1.81-14.54),F-FLT SUVmax 和 MTV 也是总生存的独立因素(P=0.021;HR,3.47;95% CI,1.2-10.01 和 P=0.029;HR,3.17;95% CI,1.12-8.95)。
预处理 F-FLT PET/CT 基于体积的代谢参数是比 F-FDG PET/CT 更好的预后预测指标。F-FLT SUVmax 和 MTV 可为接受放化疗的头颈部鳞状细胞癌患者提供重要的预后信息。